NTLA
Price
$17.65
Change
-$0.00 (-0.00%)
Updated
Oct 9 closing price
21 days until earnings call
SCPH
Price
$3.94
Change
-$0.00 (-0.00%)
Updated
Oct 9 closing price
27 days until earnings call
Ad is loading...

NTLA vs SCPH

Header iconNTLA vs SCPH Comparison
Open Charts NTLA vs SCPHBanner chart's image
Intellia Therapeutics
Price$17.65
Change-$0.00 (-0.00%)
Volume$1.51M
CapitalizationN/A
scPharmaceuticals
Price$3.94
Change-$0.00 (-0.00%)
Volume$263.34K
CapitalizationN/A
View a ticker or compare two or three
NTLA vs SCPH Comparison Chart
Loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SCPH
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
NTLA vs. SCPH commentary
Oct 11, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NTLA is a StrongSell and SCPH is a Buy.

COMPARISON
Comparison
Oct 11, 2024
Stock price -- (NTLA: $17.65 vs. SCPH: $3.94)
Brand notoriety: NTLA and SCPH are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NTLA: 108% vs. SCPH: 77%
Market capitalization -- NTLA: $2.13B vs. SCPH: $228.63M
NTLA [@Biotechnology] is valued at $2.13B. SCPH’s [@Biotechnology] market capitalization is $228.63M. The market cap for tickers in the [@Biotechnology] industry ranges from $531.34B to $0. The average market capitalization across the [@Biotechnology] industry is $2.87B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NTLA’s FA Score shows that 0 FA rating(s) are green whileSCPH’s FA Score has 0 green FA rating(s).

  • NTLA’s FA Score: 0 green, 5 red.
  • SCPH’s FA Score: 0 green, 5 red.
According to our system of comparison, NTLA is a better buy in the long-term than SCPH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NTLA’s TA Score shows that 4 TA indicator(s) are bullish while SCPH’s TA Score has 5 bullish TA indicator(s).

  • NTLA’s TA Score: 4 bullish, 3 bearish.
  • SCPH’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, NTLA is a better buy in the short-term than SCPH.

Price Growth

NTLA (@Biotechnology) experienced а -4.85% price change this week, while SCPH (@Biotechnology) price change was -9.63% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.91%. For the same industry, the average monthly price growth was +2.47%, and the average quarterly price growth was -6.27%.

Reported Earning Dates

NTLA is expected to report earnings on Feb 20, 2025.

SCPH is expected to report earnings on Mar 19, 2025.

Industries' Descriptions

@Biotechnology (+0.91% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($2.13B) has a higher market cap than SCPH($229M). SCPH YTD gains are higher at: -37.161 vs. NTLA (-42.112). SCPH has higher annual earnings (EBITDA): -51.74M vs. NTLA (-514.18M). NTLA has more cash in the bank: 691M vs. SCPH (38.5M). SCPH has less debt than NTLA: SCPH (41.4M) vs NTLA (106M). NTLA has higher revenues than SCPH: NTLA (46M) vs SCPH (24M).
NTLASCPHNTLA / SCPH
Capitalization2.13B229M931%
EBITDA-514.18M-51.74M994%
Gain YTD-42.112-37.161113%
P/E RatioN/AN/A-
Revenue46M24M192%
Total Cash691M38.5M1,795%
Total Debt106M41.4M256%
FUNDAMENTALS RATINGS
NTLA vs SCPH: Fundamental Ratings
NTLA
SCPH
OUTLOOK RATING
1..100
5953
VALUATION
overvalued / fair valued / undervalued
1..100
42
Fair valued
81
Overvalued
PROFIT vs RISK RATING
1..100
96100
SMR RATING
1..100
9699
PRICE GROWTH RATING
1..100
8585
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (42) in the Biotechnology industry is somewhat better than the same rating for SCPH (81) in the Pharmaceuticals Major industry. This means that NTLA’s stock grew somewhat faster than SCPH’s over the last 12 months.

NTLA's Profit vs Risk Rating (96) in the Biotechnology industry is in the same range as SCPH (100) in the Pharmaceuticals Major industry. This means that NTLA’s stock grew similarly to SCPH’s over the last 12 months.

NTLA's SMR Rating (96) in the Biotechnology industry is in the same range as SCPH (99) in the Pharmaceuticals Major industry. This means that NTLA’s stock grew similarly to SCPH’s over the last 12 months.

NTLA's Price Growth Rating (85) in the Biotechnology industry is in the same range as SCPH (85) in the Pharmaceuticals Major industry. This means that NTLA’s stock grew similarly to SCPH’s over the last 12 months.

NTLA's P/E Growth Rating (100) in the Biotechnology industry is in the same range as SCPH (100) in the Pharmaceuticals Major industry. This means that NTLA’s stock grew similarly to SCPH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NTLASCPH
RSI
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 28 days ago
78%
Bullish Trend 25 days ago
79%
Declines
ODDS (%)
Bearish Trend 8 days ago
85%
Bearish Trend 2 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
74%
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
78%
View a ticker or compare two or three
Ad is loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SCPH
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL229.543.77
+1.67%
Apple
SPY577.143.97
+0.69%
SPDR® S&P 500® ETF Trust
GME20.50-0.21
-1.01%
GameStop Corp
TSLA241.05-3.45
-1.41%
Tesla
BTC.X60582.100000-1549.867200
-2.49%
Bitcoin cryptocurrency

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with EDIT. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then EDIT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
-1.34%
EDIT - NTLA
75%
Closely correlated
-1.58%
BEAM - NTLA
75%
Closely correlated
+0.77%
CRSP - NTLA
71%
Closely correlated
+0.42%
VCYT - NTLA
69%
Closely correlated
-4.69%
PRME - NTLA
67%
Closely correlated
-5.82%
More

SCPH and

Correlation & Price change

A.I.dvisor indicates that over the last year, SCPH has been loosely correlated with INZY. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if SCPH jumps, then INZY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SCPH
1D Price
Change %
SCPH100%
-0.88%
INZY - SCPH
44%
Loosely correlated
-2.67%
XERS - SCPH
44%
Loosely correlated
-4.42%
BEAM - SCPH
43%
Loosely correlated
+0.77%
MGTX - SCPH
43%
Loosely correlated
+0.24%
NTLA - SCPH
43%
Loosely correlated
-1.34%
More